Loading patent…
AssigneeOncoMed Pharmaceuticals, Inc.
InventorsAustin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
Estimating the term…
The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
An isolated polynucleotide encoding an antibody that specifically binds human NOTCH2 and/or NOTCH3, wherein the antibody comprises:
An isolated polynucleotide encoding an antibody that specifically binds human NOTCH2 and/or NOTCH3, wherein the antibody comprises:
An isolated polynucleotide encoding a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:50, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:49.
An isolated polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:48, SEQ ID NO:47, SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:15, and SEQ ID NO:17.
An isolated polynucleotide deposited with ATCC as PTA-9547.
An isolated polynucleotide deposited with ATCC as PTA-10170.
Dependencies are inferred from the claim text.